Plasma and urine biomarkers in chronic kidney disease: closer to clinical application.
Plasma and urine biomarkers in chronic kidney disease: closer to clinical application.
复制标题
DOI：
10.1097/mnh.0000000000000735
复制
发表时间：
2021-11-01
影响因子：
3.2
通讯作者：
Coca SG
中科院分区：
文献类型：
--
作者：
Zabetian A;Coca SG
慢性肾病（CKD）是一种无声的疾病，在全世界范围内造成严重的健康和经济负担。由于目前可用的测量方法存在局限性，因此识别肾功能的新型预后、预测和药效生物标志物具有很强的临床价值。我们回顾了去年 CKD 生物标志物的进展。近年来最常研究的预后血浆生物标志物是血浆 TNFR1、TNFR2、KIM1 以及尿液 MCP-1 和 EGF。血浆 WFDC2、MMP-7、EFNA4、EPHA2 等新生物标志物也可能具有作为预后生物标志物的潜力。缺乏可预测治疗反应的生物标志物的数据。关于用作药效生物标志物的新型生物标志物的数据有限，但新出现的数据表明，血浆TNFR1、TNFR2、KIM-1不仅在基线时具有预后作用，而且还有助于响应治疗的时间更新的反应信号。用于预后临床风险分层、预测治疗反应和评估干预措施早期疗效的适用生物标志物的数据不断出现。尽管需要更多的研究来完善和具体的临床实用性，但似乎有足够的数据支持某些生物标志物的临床实施。
Chronic kidney disease (CKD) is a silent disease, causing significant health and economic burden worldwide. It is of strong clinical value to identify novel prognostic, predictive, and pharmacodynamic biomarkers of kidney function, as current available measures have limitations. We reviewed the advances in biomarkers in CKD over the preceding year. The most frequently studied prognostic plasma biomarkers during recent year were plasma TNFR1, TNFR2, KIM1 and urinary MCP-1 and EGF. New biomarkers such as plasma WFDC2, MMP-7, EFNA4, EPHA2 may also have potential to serve as prognostic biomarkers. There is a shortage of data on biomarkers that are predictive of response to treatments. Data on novel biomarkers to serve as pharmacodynamic biomarkers are limited, but there are emerging data that plasmaTNFR1, TNFR2, KIM-1 are not only prognostic at baseline, but can also contribute to time-updated response signals in response to therapy. Data continue to emerge on applicable biomarkers for prognostic clinical risk stratification, prediction of therapeutic response and assessment of early efficacy of interventions. Although more studies are needed for refinement and specific clinical utility, there seems to be sufficient data to support clinical implementation for some biomarkers.